Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22228040 | 1.00 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL20832767 | 0.82 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL22227921 | 0.81 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL20832770 | 0.81 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL33374588 | 0.81 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL22227917 | 0.77 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL22227918 | 0.77 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL22228058 | 0.74 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL30602670 | 0.74 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL17522167 | 0.74 | BACE1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL1 3800/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.